Some of us are participating in beta testing of generative artificial intelligence (“AI”) for legal applications in the law firm environment. So far the verdict is – associates can breathe easy, at least for now. Nothing we’ve seen is capable of replicating legal research even at a first-year level of quality.
But that doesn’t mean that AI won’t impact prescription medical product liability litigation. In particular, we’re not surprised to learn that AI is being used in the context of FDA-required adverse event reporting, purported problems with which have become one of the other side’s go-to preemption dodges. Just a few examples from a simple Google search:Continue Reading Musing about Discovery and Artificial Intelligence